lapatinib has been researched along with Hyperglycemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jo, W; Kim, CS; Kim, M; Kim, S; Lee, C; Lee, KH; Oh, J; Park, C; Park, J; Ryu, HS; Seo, JK | 1 |
| Akhtar, S; Al-Khaldi, AT; Attur, S; Benter, IF; Chandrasekhar, B; Dhaunsi, GS; Sarkhou, F; Yousif, MH | 1 |
2 other study(ies) available for lapatinib and Hyperglycemia
| Article | Year |
|---|---|
Epigenetic regulation of Neuregulin 1 promotes breast cancer progression associated to hyperglycemia.
Topics: Animals; Cell Line, Tumor; Epigenesis, Genetic; Hyperglycemia; Lapatinib; Mice; Neoplasms; Neuregulin-1 | 2023 |
The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes.
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetic Angiopathies; ErbB Receptors; Hyperglycemia; Lapatinib; Male; Molecular Targeted Therapy; Muscle, Smooth, Vascular; Phosphorylation; Primary Cell Culture; Protein Kinase Inhibitors; Quinazolines; Rats; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction | 2015 |